Jennifer Cochran, PhD, has been appointed chair of Stanfords Department of Bioengineering, which is jointly operated by the School of Medicine and School of Engineering. Her five-year term begins Sept. 1. This department has an amazing energy due in no small part to its faculty, students and staff, said Cochran, associate professor of bioengineering. These individuals nearly 500 of them, in all have an unwavering commitment to research, learning and service, and they exude a spirit of collegiality and collaboration that permeates our department and the broader Stanford community. Cochrans research is interdisciplinary, integrating chemistry, engineering and biophysics. Her laboratory focuses on protein-based drug discovery for applications including oncology and regenerative medicine, and the development of new technology for high-throughput protein analysis and engineering. In addition to being a superb scholar and educator and a proponent of deeper connections with Silicon Valleys burgeoning biotechnology activities, Jennifer is an enthusiastic, dynamic individual who will bring exciting leadership to the department and be a key contributor to the schools of Engineering and Medicine, Lloyd Minor, MD, dean of the School of Medicine, and Jennifer Widom, PhD, dean of the School of Engineering, said in a joint statement. Cochran will succeed Norbert Pelc, … Continue reading →

Rice University chemist Zachary Ball has been named director of Rices Institute of Biosciences and Bioengineering (IBB). The institute promotes interdisciplinary research and education encompassing physics, chemistry, biology and engineering.Ball succeeds Jane Grande-Allen, who will continue to serve as the Isabel C. Cameron Professor and chair of the Department of Bioengineering. Zach is our first chemist in the role of IBB director and I am very excited about how he will expand the scope of our collaborative research, said Yousif Shamoo, Rices vice provost for research, who announced the appointment. Ball sees his role with IBB as an opportunity to soften boundaries between departments at Rice and to help faculty connect with outside researchers in the Texas Medical Center. There is this inherent tension at a university, Ball said. We still need a traditional department structure, but theres also a need to empower faculty in ways that are bigger and broader than traditional departments can provide. Thats a big reason why IBB is and remains a hugely important part of the Rice research ensemble. Its uniquely situated to encourage faculty collaboration. Zach brings an objective clarity on integration, said Paul Cherukuri, IBBs executive director. He has a great analytical understanding … Continue reading →

Modeling the walk Kidziski works in the lab of Scott Delp, a professor of bioengineering and of mechanical engineering who has spent decades studying the mechanics of the human body. As part of that work, Delp and his collaborators have collected data on the movements and muscle activity of hundreds of individuals as they walk and run. With data like that, Delp, Kidziski and their team can build accurate models of how individual muscles and limbs move in response to signals from the brain. But what they could not do was predict how people relearn to walk after surgery because, as it turns out, no one is quite sure how the brain controls complex processes like walking, let alone walking through the obstacle course of daily life or relearning how to walk after surgery. Whereas weve gotten quite good at building computational models of muscles and joints and bones and how the whole system is connected how the human machine is built an open challenge is how your brain orchestrates and controls this complex dynamic system, Delp said. Machine learning, a variety of artificial intelligence, has reached a point where it could be a useful tool for modeling of the … Continue reading →

Worldwide Bioreactors and Fermenters Market 2017 presents a widespread and fundamental study of Bioreactors and Fermenters industry along with the analysis of subjective aspects which will provide key business insights to the readers. Global Bioreactors and Fermenters Market 2017 research report offers the analytical view of the industry by studying different factors like Bioreactors and Fermenters market growth, consumption volume, market trends and Bioreactors and Fermenters industry cost structures during the forecast period from 2017 to 2022. Bioreactors and Fermenters market studies the competitive landscape view of the industry. The Bioreactors and Fermenters report also includes development plans and policies along with manufacturing processes. The major regions involved in Bioreactors and Fermenters Market are (United States, EU, China, and Japan). For Sample Copy Of The Report Click Here: https://market.biz/report/global-bioreactors-and-fermenters-market-2017/94290/#inquiry Leading Manufacturers Analysis in Global Bioreactors and Fermenters Market 2017: 1 Sartorius AG ?BBI?2 Thermo Fisher3 Merck KGaA4 GE Healthcare5 Danaher (Pall)6 Eppendorf AG7 Praj Hipurity Systems8 Pierre Guerin (DCI-Biolafitte)9 ZETA10 Applikon Biotechnology11 Bioengineering AG12 Infors HT13 Solaris14 Other Bioreactors and Fermenters Market: Type Segment Analysis Single-use BioreactorsMultiple-use Bioreactors Bioreactors and Fermenters Market: Applications Segment Analysis Biopharmaceutical CompaniesCROsAcademic and Research InstitutesOthers The Bioreactors and Fermenters report does the thorough study of … Continue reading →

Israeli human-on-a-chip platform has the unique ability to predict risk of toxicity in pharma and cosmetic product candidates without animal testing After spending an average of $2.5 billion to develop a single new drug, sometimes pharma companies have to pull it from the market due to a bad outcome that was not detected in clinical studies. Thats what happened in 2000, when a promising Type 2 diabetes drug called troglitazone led to idiosyncratic (unexplained) liver damage in one of every 60,000 users. The troglitazone mystery wasnt solved until March 2016, when a novel liver-on-a-chip platform developed by Hebrew University of Jerusalem Prof. Yaakov Nahmias revealed what no animal or human tests could: even low concentrations of this drug caused liver stress before any damage could be seen. It was the first time an organ-on-chip device could predict information to help pharmaceutical companies define risk for idiosyncratic toxicity, Nahmias tells ISRAEL21c. Shortly before that study, Nahmias liver-on-a-chip had revealed a new mechanism for acetaminophen (Tylenol) poisoning. Given that about 16 percent of all FDA-approved drugs eventually show unexpected toxicity, Nahmias recognized the potential of his smart human-on-a-chip platform. He licensed the technology from the university and spun off Tissue Dynamics to … Continue reading →